Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS)
<p>Abstract</p> <p>Background</p> <p>In Japan, treatment guidelines are lacking for patients with upper gastrointestinal symptoms. We aimed to compare the efficacy of different drugs for the treatment of uninvestigated upper gastrointestinal symptoms.</p> <p>...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-05-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | http://www.biomedcentral.com/1471-230X/12/42 |
| _version_ | 1828530363653160960 |
|---|---|
| author | Sakurai Kouichi Nagahara Akihito Inoue Kazuhiko Akiyama Junichi Mabe Katsuhiro Suzuki Junichi Habu Yasuki Araki Akihiro Suzuki Tsuyoshi Satoh Katsuaki Nagami Haruhiko Harada Ryosaku Tano Nobuo Kusaka Masayasu Fujioka Yasuhiko Fujimura Toshikatsu Shigeto Nobuyuki Oumi Tsuneyo Miwa Jun Miwa Hiroto Fujimoto Kazuma Kinoshita Yoshikazu Haruma Ken |
| author_facet | Sakurai Kouichi Nagahara Akihito Inoue Kazuhiko Akiyama Junichi Mabe Katsuhiro Suzuki Junichi Habu Yasuki Araki Akihiro Suzuki Tsuyoshi Satoh Katsuaki Nagami Haruhiko Harada Ryosaku Tano Nobuo Kusaka Masayasu Fujioka Yasuhiko Fujimura Toshikatsu Shigeto Nobuyuki Oumi Tsuneyo Miwa Jun Miwa Hiroto Fujimoto Kazuma Kinoshita Yoshikazu Haruma Ken |
| author_sort | Sakurai Kouichi |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>In Japan, treatment guidelines are lacking for patients with upper gastrointestinal symptoms. We aimed to compare the efficacy of different drugs for the treatment of uninvestigated upper gastrointestinal symptoms.</p> <p>Methods</p> <p>This was a randomized, open-label, parallel-group multicenter study. <it>Helicobacter pylori</it>-negative, endoscopically uninvestigated patients ≥ 20 years of age with upper gastrointestinal symptoms of at least moderate severity (Global Overall Symptom score [GOS] ≥ 4 on a 7-point Likert scale) were randomized to treatment with omeprazole (10 mg once daily), famotidine (10 mg twice daily), mosapride (5 mg three times daily) or teprenone (50 mg three times daily). The primary endpoint was sufficient relief of upper gastrointestinal symptoms after 4 weeks of treatment (GOS ≤ 2). UMIN clinical trial registration number: UMIN000005399.</p> <p>Results</p> <p>Of 471 randomized patients, 454 were included in the full analysis set. After 4 weeks of treatment, sufficient symptom relief was achieved by 66.9% of patients in the omeprazole group, compared with 41.0%, 36.3% and 32.3% in the famotidine, mosapride and teprenone groups, respectively (all, p < 0.001 vs omeprazole). There were no treatment-related adverse events.</p> <p>Conclusions</p> <p>The favorable efficacy and safety profiles of omeprazole in relieving uninvestigated upper gastrointestinal symptoms support its use as first-line treatment in this patient group in Japan. Patients who show no improvement in symptoms despite PPI use, and those with alarm symptoms (such as vomiting, GI bleeding or acute weight loss) should receive further investigation, including prompt referral for endoscopy.</p> <p>Trial registration</p> <p>UMIN000005399.</p> |
| first_indexed | 2024-12-11T22:22:41Z |
| format | Article |
| id | doaj.art-c190ffbf21ab40fd9c3fbc3e290d4fe0 |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-12-11T22:22:41Z |
| publishDate | 2012-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-c190ffbf21ab40fd9c3fbc3e290d4fe02022-12-22T00:48:24ZengBMCBMC Gastroenterology1471-230X2012-05-011214210.1186/1471-230X-12-42Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS)Sakurai KouichiNagahara AkihitoInoue KazuhikoAkiyama JunichiMabe KatsuhiroSuzuki JunichiHabu YasukiAraki AkihiroSuzuki TsuyoshiSatoh KatsuakiNagami HaruhikoHarada RyosakuTano NobuoKusaka MasayasuFujioka YasuhikoFujimura ToshikatsuShigeto NobuyukiOumi TsuneyoMiwa JunMiwa HirotoFujimoto KazumaKinoshita YoshikazuHaruma Ken<p>Abstract</p> <p>Background</p> <p>In Japan, treatment guidelines are lacking for patients with upper gastrointestinal symptoms. We aimed to compare the efficacy of different drugs for the treatment of uninvestigated upper gastrointestinal symptoms.</p> <p>Methods</p> <p>This was a randomized, open-label, parallel-group multicenter study. <it>Helicobacter pylori</it>-negative, endoscopically uninvestigated patients ≥ 20 years of age with upper gastrointestinal symptoms of at least moderate severity (Global Overall Symptom score [GOS] ≥ 4 on a 7-point Likert scale) were randomized to treatment with omeprazole (10 mg once daily), famotidine (10 mg twice daily), mosapride (5 mg three times daily) or teprenone (50 mg three times daily). The primary endpoint was sufficient relief of upper gastrointestinal symptoms after 4 weeks of treatment (GOS ≤ 2). UMIN clinical trial registration number: UMIN000005399.</p> <p>Results</p> <p>Of 471 randomized patients, 454 were included in the full analysis set. After 4 weeks of treatment, sufficient symptom relief was achieved by 66.9% of patients in the omeprazole group, compared with 41.0%, 36.3% and 32.3% in the famotidine, mosapride and teprenone groups, respectively (all, p < 0.001 vs omeprazole). There were no treatment-related adverse events.</p> <p>Conclusions</p> <p>The favorable efficacy and safety profiles of omeprazole in relieving uninvestigated upper gastrointestinal symptoms support its use as first-line treatment in this patient group in Japan. Patients who show no improvement in symptoms despite PPI use, and those with alarm symptoms (such as vomiting, GI bleeding or acute weight loss) should receive further investigation, including prompt referral for endoscopy.</p> <p>Trial registration</p> <p>UMIN000005399.</p>http://www.biomedcentral.com/1471-230X/12/42OmeprazoleFamotidineMosaprideTeprenoneUninvestigated upper gastrointestinal symptoms |
| spellingShingle | Sakurai Kouichi Nagahara Akihito Inoue Kazuhiko Akiyama Junichi Mabe Katsuhiro Suzuki Junichi Habu Yasuki Araki Akihiro Suzuki Tsuyoshi Satoh Katsuaki Nagami Haruhiko Harada Ryosaku Tano Nobuo Kusaka Masayasu Fujioka Yasuhiko Fujimura Toshikatsu Shigeto Nobuyuki Oumi Tsuneyo Miwa Jun Miwa Hiroto Fujimoto Kazuma Kinoshita Yoshikazu Haruma Ken Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS) BMC Gastroenterology Omeprazole Famotidine Mosapride Teprenone Uninvestigated upper gastrointestinal symptoms |
| title | Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS) |
| title_full | Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS) |
| title_fullStr | Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS) |
| title_full_unstemmed | Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS) |
| title_short | Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS) |
| title_sort | efficacy of omeprazole famotidine mosapride and teprenone in patients with upper gastrointestinal symptoms an omeprazole controlled randomized study j focus |
| topic | Omeprazole Famotidine Mosapride Teprenone Uninvestigated upper gastrointestinal symptoms |
| url | http://www.biomedcentral.com/1471-230X/12/42 |
| work_keys_str_mv | AT sakuraikouichi efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT nagaharaakihito efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT inouekazuhiko efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT akiyamajunichi efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT mabekatsuhiro efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT suzukijunichi efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT habuyasuki efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT arakiakihiro efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT suzukitsuyoshi efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT satohkatsuaki efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT nagamiharuhiko efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT haradaryosaku efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT tanonobuo efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT kusakamasayasu efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT fujiokayasuhiko efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT fujimuratoshikatsu efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT shigetonobuyuki efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT oumitsuneyo efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT miwajun efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT miwahiroto efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT fujimotokazuma efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT kinoshitayoshikazu efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus AT harumaken efficacyofomeprazolefamotidinemosaprideandteprenoneinpatientswithuppergastrointestinalsymptomsanomeprazolecontrolledrandomizedstudyjfocus |